Presented by Olink and Illumina
Empowering Genomics with Proteomics in Cancer Research
Michael Förster, PhD | Scientific Director, Oncology & Rare Diseases, Olink Proteomics
Olink Proteomics has been widely adopted due to its scalability to help answer research questions aiming to elucidate signaling pathways in health and diseases, novel mechanisms of drug action or as a tool to identify actionable biomarker signatures with a prognostic/predictive value. With its expanding protein library, covering major biological pathways and >600 known drug targets, the Olink platform has been applied in the study of a wide variety of both hematological and solid cancers.
The Latest Advancements in Genomics and Multiomic Research
Lisa Lock, PhD | Sr. Genomics Specialist, Canada, Illumina
Advances in genomic technologies are giving researchers the tools to access more molecular data than ever before, enabling transcriptomics, epigenetics, proteomics and beyond. To see the full picture of biology, scientists are increasingly turning towards a multiomic approach that integrates these various omic methods. Come learn more about the latest advancements in genomics and miltiomic research.